152 related articles for article (PubMed ID: 24405333)
1. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.
Quan ML; Wong PC; Wang C; Woerner F; Smallheer JM; Barbera FA; Bozarth JM; Brown RL; Harpel MR; Luettgen JM; Morin PE; Peterson T; Ramamurthy V; Rendina AR; Rossi KA; Watson CA; Wei A; Zhang G; Seiffert D; Wexler RR
J Med Chem; 2014 Feb; 57(3):955-69. PubMed ID: 24405333
[TBL] [Abstract][Full Text] [Related]
2. Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.
Hangeland JJ; Friends TJ; Rossi KA; Smallheer JM; Wang C; Sun Z; Corte JR; Fang T; Wong PC; Rendina AR; Barbera FA; Bozarth JM; Luettgen JM; Watson CA; Zhang G; Wei A; Ramamurthy V; Morin PE; Bisacchi GS; Subramaniam S; Arunachalam P; Mathur A; Seiffert DA; Wexler RR; Quan ML
J Med Chem; 2014 Dec; 57(23):9915-32. PubMed ID: 25405503
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
Quan ML; Liauw AY; Ellis CD; Pruitt JR; Carini DJ; Bostrom LL; Huang PP; Harrison K; Knabb RM; Thoolen MJ; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2752-9. PubMed ID: 10425086
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
10. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
[TBL] [Abstract][Full Text] [Related]
11. New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in vivo antithrombotic evaluation and molecular docking.
Amin KM; Abdel Gawad NM; Abdel Rahman DE; El Ashry MK
Bioorg Chem; 2014 Feb; 52():31-43. PubMed ID: 24316885
[TBL] [Abstract][Full Text] [Related]
12. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.
Wong PC; Quan ML; Watson CA; Crain EJ; Harpel MR; Rendina AR; Luettgen JM; Wexler RR; Schumacher WA; Seiffert DA
J Thromb Thrombolysis; 2015 Nov; 40(4):416-23. PubMed ID: 26249722
[TBL] [Abstract][Full Text] [Related]
13. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
14. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
Corte JR; Pinto DJP; Fang T; Osuna H; Yang W; Wang Y; Lai A; Clark CG; Sun JH; Rampulla R; Mathur A; Kaspady M; Neithnadka PR; Li YC; Rossi KA; Myers JE; Sheriff S; Lou Z; Harper TW; Huang C; Zheng JJ; Bozarth JM; Wu Y; Wong PC; Crain EJ; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
J Med Chem; 2020 Jan; 63(2):784-803. PubMed ID: 31833761
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
Yang W; Wang Y; Lai A; Clark CG; Corte JR; Fang T; Gilligan PJ; Jeon Y; Pabbisetty KB; Rampulla RA; Mathur A; Kaspady M; Neithnadka PR; Arumugam A; Raju S; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Chacko SA; Bozarth JM; Wu Y; Crain EJ; Wong PC; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
J Med Chem; 2020 Jul; 63(13):7226-7242. PubMed ID: 32456431
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Hase Y; Uchida I; Aisaka K; Katoh S; Cho H
J Med Chem; 2005 May; 48(10):3586-604. PubMed ID: 15887966
[TBL] [Abstract][Full Text] [Related]
18. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
19. Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa.
Buchanan MS; Carroll AR; Wessling D; Jobling M; Avery VM; Davis RA; Feng Y; Xue Y; Oster L; Fex T; Deinum J; Hooper JN; Quinn RJ
J Med Chem; 2008 Jun; 51(12):3583-7. PubMed ID: 18510371
[TBL] [Abstract][Full Text] [Related]
20. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
